A common variant in a gene that doubles the chance of hepatitis C treatment working in people coinfected with HIV may also nearly double the risk of death in patients taking antiretroviral therapy.
A study from Poland found that patients with the so-called 'CC' variant of mutation site rs 1979860 of the IL28B gene were 80% more likely to die during follow-up than patients with the other two possible variants, CT and TT (the letters refer to the particular bases, cytosine and thymine, at that point in the DNA molecule).
Read more.....
0 comments:
Post a Comment